Revolutionary Nasal Spray: ENA Respiratory's INNA-051 for Respiratory Virus Protection (2025)

Imagine a world where the sniffles of a cold or the chills of the flu don't spiral into life-threatening crises – but what if a simple nasal spray could empower your body's own defenses to fight back? That's the groundbreaking promise of ENA Respiratory's latest funding boost, and trust me, it's sparking conversations about the future of health protection.

ENA Respiratory, a forward-thinking pharmaceutical firm focused on creating antiviral solutions that supercharge the body's innate defenses against symptomatic viral respiratory infections, has just secured a whopping US$22.4 million (equivalent to AU$34 million) through its Series B financing round. This exciting development was backed by loyal supporters like Brandon Capital and Uniseed, with fresh involvement from Stoic Venture Capital. Plus, it brought in global heavyweights such as the Gates Foundation and the previously mentioned Flu Lab, signaling strong international confidence in their vision.

These funds are earmarked for advancing the Phase II clinical trials of INNA-051, their innovative virus-agnostic once-weekly dry powder nasal spray. Essentially, INNA-051 works by priming the natural antiviral shields right in the nose – the primary entry point for viruses like the common cold, influenza, RSV, and even coronaviruses. This preparation helps your body mount a faster, more effective response when these pathogens strike. Early preclinical and clinical data are promising, suggesting that INNA-051 could shorten the time you're down with symptoms, stop infections from spreading to the lungs, and cut down on serious complications. But here's where it gets controversial – is this approach really a game-changer, or could it lead to over-reliance on prevention at the expense of traditional vaccines? We'll dive deeper into that later.

The upcoming Phase II community study, cleverly dubbed 'POSITS,' will rigorously test the safety, tolerability, and effectiveness of using INNA-051 for up to three months. Researchers will measure its impact on the occurrence, length, and intensity of symptomatic infections from everyday respiratory viruses, including influenza, RSV, rhinovirus, and coronaviruses. The study targets young adults who are more vulnerable due to living or working in densely packed settings, like bustling city apartments or high-traffic offices where germs thrive. Set to kick off soon, it aims to enroll up to 1,100 participants during the 2025-2026 North American respiratory season. Leading the charge as Principal Investigator is Dr. Justin Ortiz, MD, MS, a respected Professor of Medicine at the University of Maryland's esteemed Center for Vaccine Development and Global Health (CVDGH). He's a global expert in combating respiratory viruses, bringing years of experience in protection and control strategies to the table.

At its core, INNA-051 is designed to lower the risk of severe outcomes for those most at risk of serious illness. Think about it: Seasonal infections like the flu strain healthcare systems and economies, leading to expensive hospital stays and lost workdays. The toll is heaviest on people with underlying conditions such as asthma, COPD, heart disease, kidney issues, diabetes, weakened immune systems, and cancer – groups facing dramatically higher chances of complications. In the U.S. alone, these viruses caused over a million hospitalizations and up to 200,000 deaths in 2025, a staggering reminder of the unseen burden on society.

ENA Respiratory's CEO, Dr. Christophe Demaison, PhD, expressed his enthusiasm: 'This investment is a pivotal achievement for ENA Respiratory, propelling INNA-051 into a real-world community Phase II trial. With a diverse global investor group and unwavering support from our Australian backers, we're poised to assess how our weekly powder nasal spray, which activates the body's built-in antiviral responses, performs outside the lab. It's bringing us closer to helping those who need it most. This represents an exhilarating leap in our quest to offer a pioneering preventive tool for shielding at-risk groups, potentially lightening the worldwide load of respiratory viruses.'

Backing this up, research from the Global Allergy & Airways Patient Platform – a patient advocacy group that ENA supported – surveyed over 3,000 U.S. adults with relevant health challenges. The results showed overwhelming support for a hassle-free preventive like INNA-051. Most respondents who consider themselves high-risk for hospitalization or emergency care due to viral respiratory issues said they'd gladly use such a product weekly during winter. This underscores a glaring gap in current options and hints at widespread adoption for treatments that could slash hospital visits, improve overall wellness, and relieve strain on medical services. And this is the part most people miss – could widespread use of such a spray reduce the need for flu shots, stirring debates about public health priorities? It's a hot topic worth pondering.

Chris Smith, PhD, Non-Executive Director at ENA Respiratory and a partner at Brandon Capital, added: 'Brandon Capital has been with ENA Respiratory from the start, drawn to INNA-051's ability to revolutionize how we prevent and handle respiratory infections. With this fresh funding and the imminent Phase 2 trial in the U.S., ENA is on track to provide a treatment that might safeguard millions of vulnerable individuals globally.'

-ENDS-

About us:

About ENA Respiratory

ENA Respiratory is an emerging pharmaceutical company dedicated to combating respiratory viral infections by developing enhancers that strengthen the body's first-line defenses locally against invading pathogens. Since their approach doesn't target specific viruses, it provides a versatile shield against both familiar and new respiratory viruses where vaccines or targeted antivirals fall short or are unavailable.

Their flagship product, INNA-051, is in development as an easy-to-use, once-a-week nasal dry powder spray aimed at lessening the effects of viral respiratory infections and averting serious issues in susceptible populations. This includes seniors, those with chronic conditions (such as lung diseases, diabetes, kidney problems, and heart conditions), and people in high-risk jobs (like firefighters, military personnel, or frontline workers in essential services).

Scientifically, INNA-051 acts as a strong activator of toll-like receptor 2/6 (TLR2/6), which is crucial for detecting harmful invaders and boosting the immune system's initial reactions. To put it simply for beginners, TLR2/6 are like molecular sentinels on your cells that sound the alarm when danger approaches, rallying defenses such as interferons (proteins that block viral replication). With a safety record that supports repeated use over seasons, INNA-051 has shown in tests that it speeds up clearing viruses and enhances antiviral protections, including types I and III interferons, as demonstrated in a Phase IIa study using a controlled influenza challenge in humans.

Based in Melbourne, Australia, with U.S. operations, ENA's investors comprise Brandon Capital, Flu Lab, the Gates Foundation, the Minderoo Foundation, Stoic Venture Capital, and Uniseed. The company collaborates with the U.S. COPD Foundation to focus on patient-centered trials for INNA-051 in COPD patients and has secured government contracts from the U.S. They've also participated in BLUE KNIGHT™, a collaborative effort by Johnson & Johnson Innovation and BARDA to fast-track pandemic-ready innovations.